Aspen Sigma SENS Cautionary Renewal

Aspen Pharmacare Holdings Limited

(Incorporated in the Republic of South Africa)

(Registration number 1985/002935/06)

Share code: APN ISIN: ZAE000066692

(“Aspen”)

Renewal of detailed cautionary announcement

Aspen shareholders are referred to the detailed cautionary announcement dated 21 May 2010 and are advised that Aspen Global Incorporated (“Aspen Global”) has submitted to Sigma Pharmaceuticals Limited (“Sigma”), a confirmed offer to acquire the whole of Sigma (the “Transaction”) for cash at a price per Sigma share of A$0.55 (approx. ZAR3.58)1 (the “Offer”) which implies an equity value of A$648 million (approx. ZAR4 219 million)1 based on 1,178.6 million Sigma shares outstanding.

Aspen has proposed that the Transaction be executed via a scheme of arrangement. The Offer is also subject to numerous conditions precedent, including the satisfactory completion by Aspen of a final due diligence investigation, the conclusion of a scheme implementation agreement and fulfillment of all necessary regulatory approvals.

Aspen shareholders are referred to the announcement released today by Sigma, which is available at the ASX website www.asx.com.au.

Accordingly, Aspen shareholders are advised to continue to exercise caution when dealing in Aspen shares until a further announcement is made.

1 Based on AUD/ZAR exchange rate of 0.1536 as at 7 July 2010 (Source: Bloomberg).

Woodmead

7 July 2010

我们的使命

更多详情

致力于提高患者的生命健康和质量

我们的愿景

更多详情

作为一个负责任的企业公民,在全球提高优质和患者可及的药物,传递我们的价值。

我们的价值观

更多详情

我们的价值观是爱施健存立和发展的基石。集团上下以此为指引,为实现集团目标而共同奋斗。

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.